Nerviano Medical Sciences establishes its Scientific Advisory Board
Nerviano, IT and Boston, Mass, 26 March, 2024 – Nerviano Medical Sciences S.r.l. (NMS), and Nerviano Medical Sciences, Inc. (NMS-US), a wholly owned subsidiary of NMS S.r.l., focused on the discovery and development of oncology drugs and the largest oncological R&D company in Italy, announced the formation of their Scientific Advisory Board (SAB), with the […]
Nerviano Medical Sciences S.r.l. to present data on its platform of payload linkers for ADC conjugation at the World ADC Summit 2024 in London, UK (March 12th-15th, 2024)
Nerviano Medical Sciences S.r.l. (NMS), a member of NMS Group S.p.A and a clinical stage biotech discovering and developing innovative therapies for the treatment of cancer, is proud to announce its participation to the World ADC 2024 summit that will be held in London, UK (World ADC Europe) from March 12th to March 15th, 2024, with […]
Nerviano Medical Sciences received European Medicines Agency (EMA) Orphan Drug Designation for its next-generation FLT3 inhibitor NMS-03592088 for treatment of Acute Myeloid Leukemia
NERVIANO, IT and BOSTON, Mass, 4 March, 2024 – Nerviano Medical Sciences S.r.l. (NMS), a part of NMS Group S.p.A. (NMS Group) and Nerviano Medical Sciences, Inc. (NMS-US), a wholly owned subsidiary of NMS Group, focused on the discovery and development of oncology drugs and the largest oncological R&D company in Italy, announced that European […]
New European Patent Office study: NMS S.r.l. top applicant in Italy during the 2002-2021 period
New European Patent Office study: NMS srl top applicant in Italy during the 2002-2021 period Nerviano, 1 February 2024 The new study “Patents and Innovation against Cancer”, just released today by the European Patent Office (EPO), reports Italy among top European nations in innovation to fight cancer. In the past 20 years close to 2 […]
Nerviano Medical Sciences received Orphan Drug Designation for its next-generation FLT3 inhibitor NMS-03592088 for treatment of Acute Myeloid Leukemia
NERVIANO, IT and BOSTON, Mass, 9 January, 2024 – Nerviano Medical Sciences S.r.l. (NMS), a part of NMS Group S.p.A. (NMS Group) and Nerviano Medical Sciences, Inc. (NMS-US), a wholly owned subsidiary of NMS Group, focused on the discovery and development of oncology drugs and the largest oncological R&D company in Italy, announced that the […]
Iktos and Nerviano Medical Sciences S.r.l Announce Collaboration in Artificial Intelligence for New Drug Discovery
NERVIANO Italy and PARIS France, January 8, 2024 – Iktos, a company specialized in Artificial Intelligence for new drug design, and Nerviano Medical Sciences S.r.l (NMS), a leading Italian clinical stage biotech discovering and developing innovative therapies for the treatment of cancer, today announced a collaboration agreement in AI for unprecedented kinase project. As per […]
Nerviano Medical Sciences S.r.l.’s Landmark Article in The Journal of Organic Chemistry
Nerviano Medical Sciences Srl (NMS) is pleased to announce the publication of the hot-off-the-press article “Photocatalytic Radical Coupling of Organoborates with α-Halogenated Electron-Poor Olefins” published in The Journal of Organic Chemistry (https://doi.org/10.1021/acs.joc.3c02386) . The paper reports the unprecedented light-mediated construction of elaborated α-halo-derivatives, useful intermediates in organic synthesis. This brilliant achievement was accomplished by […]
Nerviano Medical Sciences and Italfarmaco Announce Licensing of Linker-Payload Technology to Develop and Commercialize a Novel Peptide-Drug Conjugate
NERVIANO and MILAN, Italy, December 14, 2023 – Nerviano Medical Sciences S.r.l. (NMS), a clinical-stage biotechnology company member of NMS group, announced the signing of a license agreement with Italfarmaco S.p.A. (ITF), a specialty pharmaceutical company, to develop and commercialize a novel peptide-drug conjugate (PDC). Under the terms of the agreement, ITF will use NMS’s […]
Serena Alvino Appointed as Chief Legal, Biotech & Transaction NMS S.r.l., Bringing Extensive Global Biopharmaceutical Experience
NERVIANO, IT and BOSTON, Mass, December 1, 2023 – Nerviano Medical Sciences S.r.l. (NMS), a part of NMS Group S.p.A. (NMS Group) and Nerviano Medical Sciences, Inc., a wholly owned subsidiary of NMS Group, focused on the discovery and development of oncology drugs and the largest oncological R&D company in Italy, announced today the appointment […]
NMS S.r.l. proudly takes part of the Mentoring Program 2024 organized by the Italian Chemical Society
We are pleased to announce that Dr. Gianluca Papeo and Dr. Maurizio Pulici from NMS Srl are invited to be part of the permanent round table of the Pharmaceutical Division of the Italian Chemical Society (SCI) which gathers representative of the Italian Pharmaceutical industry and the Academic world to liaise their relationships under the patronage […]
